A new method for measuring of molecular mobility in glassy materials has been developed using terahertz spectroscopy. The absorption level of amorphous drugs at terahertz frequencies below Tg correlates with the stability of the drug as an amorphous solid.  The molecular mobility responsible for the glass crystallisation significantly decreases at around a universal value of 0.67 Tg. This explains why the commonly used rules of thumb for glasses to remain stable below 0.8 Tg or Tg – 20 K do not work reliably.

These results reveal a unique and completely novel opportunity to predict and test the stability of amorphous drugs by measuring the molecular mobility below the glass transition temperature of drugs and formulations at terahertz frequencies. It is not possible to measure this information using conventional dielectric spectroscopy due to the practical difficulties of measuring at low temperatures.

We are interested in meeting industrial contacts who would be willing to collaborate on developing this method further.

To find out more please see Juraj Sibik at the 9th World Meeting in Lisbon, on 2nd April between 12.30 and 15.00 at poster panel 190 or email Axel Zeitler (This email address is being protected from spambots. You need JavaScript enabled to view it.).

Visit for more information of our group.

Tuesday, 11 February 2014 14:41

Privacy Policy


This policy explains what information we gather when you visit our web site, and explains how that information is used.


This website uses cookies, which are small pieces of information that are issued to your computer or other internet-enabled device when you visit the website. Cookies are stored by your browser and hard drive and are used to distinguish you from other visitors to the site.

Cookies are small files which sit on your computer and record specific interactions between you and this website, and in some cases, other websites. This information is sometimes shared with the University of Cambridge, and in other cases, third parties. Below is more detail about the cookies we use, what they record and who the information is shared with. You are of course free to disable cookies.

Functionality lost by disabling cookies or not giving consent

If you disable cookies, or don't opt in to receive them from these sections of our site, some functionality will not be available.

How to disable cookies

Your web browser will have an option you select which will block cookies. Below are links to popular web browsers, and how to block cookies using them.


Internet Explorer

Google Chrome


Other web browsers

Cookies set by third party websites

Name Used by Description More information
Google Analytics We use Google Analytics to see how people use our website. This helps us improve it. The data we have is anonymised. Google’s Privacy Policy

Data collected

In common with most web sites, this site automatically logs certain information about every request made of it (see below for more details). This information is used for system administration, for bug tracking, and for producing usage statistics. 

We may collect and process the following data about you:

  • Information that you provide by filling in forms provided on this website for a specific purpose. By supplying this information you are consenting to the PSSRC holding and using it for the purposes for which it was provided.
  • If you contact us, we may keep a record of that correspondence.

Logged data

The following data is automatically collected for each request:

  • The name or network address of the computer making the request. Note that under some (but not all) circumstances it may be possible to infer from this the identity of the person making the request. Note also that the data recorded may be that of a web proxy rather than that of the originating client
  • The username, when known during authenticated (logged in) access to the site
  • The date and time of connection
  • The HTTP request, which contains the identification of the document requested
  • The status code of the request (success or failure etc.)
  • The number of data bytes sent in response
  • The contents of the HTTP Referrer header supplied by the browser
  • The content of the HTTP User-Agent header supplied by the browser

Logging of additional data may be enabled temporarily from time to time for specific purposes.

In addition, the computers on which the web site is hosted keep records of attempts (authorised and unauthorised) to use them for purposes other than access to the web server. This data typically includes:

  • the date and time of the attempt,
  • the service to which access was attempted,
  • the name or network address of the computer making the connection,
  • and may include details of what was done or was attempted to be done.

Disclosure and uses of personal information

We use information held about you in the following ways:

  • to ensure that content from our website is presented in the most effective manner for you and for your computer or device by gathering aggregate information about our users using it to analyse the effectiveness and popularity of this website
  • to allow you to participate in interactive features of our service, when you choose to do so

We may disclose your personal information to third parties in the following circumstances:

  • if we have obtained your consent to do so
  • when we are required or authorised by law, court order, regulatory or governmental authority to disclose your personal data

Relevant subsets of this data may be passed to computer security teams as part of investigations of computer misuse involving this site.

In addition, this site uses Google Analytics to help us analyse site usage and to improve it. To support this, selected information about your interaction with the site is sent to Google for them to analyse on our behalf. For more information about Google Analytics see

Links to other websites

This website contains links to and from third-party sites. This policy only covers use of cookies on this site. You should consult privacy and cookie policies on third-party sites before you submit and personal data. The PSSRC is not responsible for any cookies that may be set by third party websites that are linked to from pages on


Sunday, 10 November 2013 21:46

Professor Stane Srčič

1980 MSc in Pharmaceutical Technology, University of Ljubljana
1985 PhD in Pharmaceutical Technology, University of Ljubljana

Contact Details

University of Ljubljana,
Faculty of Pharmacy
Aškerčeva cesta 7
SI-1000 Ljubljana

Tel.: +386 1 47 69 500
Tel.: +386 1 47 69 602 (dir. line)
Fax: +386 1 42 58 031
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Short CV & Main Research Interests

Stane Srčič is a Professor of Pharmaceutics and Head of the Department of Pharmaceutics at the University of Ljubljana, where he held the position of Vice-Dean between 1996 and 2000. Following a postdoc at the Faculty of Pharmacy, University of Regensburg, Germany from 1987-88 he was Assistant and Associate Professor in Ljubljana before becoming a full Professor and taking on the role of Head of Department. He is also the coordinator for MSc Industrial Pharmacy Program. At present Stane serves on the editorial board of a number of journals in the field holds a visiting professorship at the University of Sarajewo.

His main research interest spans the fields of thermal analysis, atomic force microscopy, nano indentation, inverse gas chromatography, nuclear quadrupole resonance, pellets and coating as well as tablets and controlled release.



Tuesday, 08 January 2013 16:31

Professor Chris Vervaet

Contact Details

Laboratory of Pharmaceutical Technology
Ghent University
Harelbekestraat 72
B-9000 Gent

Tel.: + 32 (0) 9 264 80 69
Fax: + 32 (0) 9 222 82 36

University website

Main Research Interests

The main research interest of Professor Vervaet is in the field of solid dosage forms, especially pellets, sustained release matrix formulations, coprocessing, tabletting and pediatric formulations.

Short CV

Chris Vervaet obtained his degree as a Pharmacist in 1992 and his Ph.D. degree in 1997 at Ghent University. After a post-doctoral stay at the Aerosol Research Group at the Virginia Commonwealth University (Richmond, Virginia, United States) he returned to the Laboratory of Pharmaceutical Technology in July 1999 where he was appointed as professor in October 2000.

Tuesday, 08 January 2013 16:26

Professor Jean Paul Remon

Contact Details

Laboratory of Pharmaceutical Technology
Ghent University
Harelbekestraat 72
B-9000 Gent

Tel.: + 32 (0) 9 264 80 54
Fax: + 32 (0) 9 222 82 36

University website

Main Research Interests

The main research interest of Professor Remon is in the field of solid dosage forms, especially pellets, sustained release matrix formulations, coprocessing, bioadhesion and pediatric formulations.

Short CV

Jean Paul Remon obtained his degree as a Pharmacist in 1973, a degree in Industrial Pharmacy in 1974 and his Ph.D. degree in 1981 at Ghent University. After research fellowships at University of Keele (UK) (Biochemistry Research Unit) in 1983 and at the College of Pharmacy and Science (Philadelphia, US) in 1984, he became professor at Ghent University in 1985.

He is member of several pharmaceutical societies (APV, AAPS, APGI, Controlled Release Society) and became a AAPS Fellow in 2005.

Since 1996 he is Dean of the Faculty of Pharmaceutical Sciences (Ghent University).

He is co-author of more than 200 research papers.

Tuesday, 08 January 2013 16:23

Professor Anne Juppo

M.Sc., Helsinki, 1991
Ph.D., Helsinki, 1995
Docent, Helsinki, 1997
Adjunct professor, Helsinki, 2003
Professor in Industrial Pharmacy, Helsinki, 2006

Contact Details

University of Helsinki
Faculty of Pharmacy, Formulation and Industrial Pharmacy
P.O. Box 56 (Viikinkaari 5 E)
00014 University of Helsinki

Phone: +358-294159162 

Main Research Interests

Prof. Anne M. Juppo holds the professorship in Industrial Pharmacy in University of Helsinki since 2006. Industrial pharmacy is a discipline which includes manufacturing, development, marketing and distribution of drug products including quality assurance of these activities. Her research at the University of Helsinki is focused at the moment on the novel technologies (excipients and processes) for pharmaceutical solid formulation on biopharmaceuticals and solid formulations for veterinary, peadiatric and elderly patients. 

Short CV

Her previous appointments are in pharmaceutical industry: AstraZeneca R&D Mölndal (1996-2006), where she worked as research scientist, project leader, team manager and as Principal Scientist in Product Development. Her areas of interest in these positions were controlled release preparations, particle technology, pellet technology and polymer coatings. In addition to the industrial position she had an adjunct professorship (2003-2005) in University of Helsinki. Prior to her position at AstraZeneca, she worked with solid state and particle characterisation in Orion Pharma, Finland (1992-1995).

Tuesday, 08 January 2013 15:47

Professor Jörg Breitkreutz

Staatsexamen Pharmazie, Münster, 1991
Diplompharmazeut, Greifswald, 1992
Dr. rer. nat. (Pharmaceutical Technology), Münster, 1996
Habilitation (Pharmaceutical Technology), Münster, 2004
Professor for Pharmaceutical Technology, Düsseldorf, 2004

Contact Details

Heinrich-Heine-University Düsseldorf
Institute of Pharmaceutics and Biopharmaceutics
Universitätsstrasse 1
40225 Düsseldorf

Tel.: +49-211-81-14220
Fax: +49-211-81-14251

Main Research Interests

Prof. Jörg Breitkreutz holds the professorship in Pharmaceutical Technology in University of Düsseldorf since 2004. His research is focused on paediatric formulations, pharmaceutical excipients, drug delivery devices, process analytical technologies and taste prediction. He is involved in numerous development projects for paediatric drugs and holds several patents for paediatric medicines.

Short CV

Jörg Breitkreutz studied Pharmacy from 1987 to 1991 at the Westphalian Wilhelms-University of Münster, Germany. He finished his PhD in 1996 at the Institute for Pharmaceutical Technology and Biopharmaceutics in Münster under supervision of Prof. Rüdiger Gröning. From 1996 to 1997 he joined Thiemann Arzneimittel GmbH in Waltrop, Germany, as the Head of Product Coordination. In 1997 he went back to the university in Münster to work on his habilitation thesis (2004) on pediatric drug formulations. In 2004 he became professor for pharmaceutical technology at the Institute of Pharmaceutics and Biopharmaceutics at the Heinrich-Heine-University in Düsseldorf, Germany. Since 2009 he is the head of the Pharmacy department in Düsseldorf. He currently is member of the European Paediatric Formulation Initiative (EuPFI) and board member of the International Association for Pharmaceutical Technology (APV).